Overtreatment is considered harmful in terms of decreasing quality of life, wasting resources, and environmental damage.1–3 These risks are especially relevant when considering adjuvant chemotherapy ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...